Alkermes Announces Priority Review by FDA for VIVITROL® for Opioid Dependence

Alkermes Announces Priority Review by FDA for VIVITROL® for Opioid Dependence
Alkermes, Inc. (NASDAQ: ALKS) today announced that the supplemental New Drug Application (sNDA) for VIVITROL ® (naltrexone for extended-release injectable suspension) for opioid dependence has been designated a priority review by the U.S. Food and Drug Administration (FDA). The designation is assigned to drugs that offer major advances in treatment, or provide a treatment where no adequate …

Read more on SYS-CON Media

More Meth Drug Addiction Info:

• SIIU (SNDA Impression Illustration Union) minisite intropage designed
• Bringing Health Information to the Community (BHIC) » Blog Archive …
• Priority Review For Alkermes Drug | Daily Markets
• 5 Stock Charts Telling Us To Sell-GOOG, SNDA, FWLT, SPLS, FSLR …
• A New Way of Looking at Addiction Treatment | Addiction Treatment
• Priority Review For Alkermes Drug | G2Roms.com
• Obesity Musings On Alkermes, J&J News | The Haystack
• FDA to Reconsider Ban on Gay Blood Donors
• FDA warns weight loss drug may cause liver damage in rare cases
• FDA warns that widely used heartburn medications may cause hip …